- Risk of stroke or systemic embolism associated with apixaban was lower than that with warfarin in patients weighing 121 to 140 kg
- In the >140 kg cohort, there were only 2 events in the apixaban group and 1 in the warfarin group; therefore, comparison between the 2 groups was not possible
- There was no difference between apixaban and warfarin in relation to all-cause death for either of the weight groups
| Event – Efficacy endpoints | Rate (n) | HR (95% CI) | ||
|---|---|---|---|---|
| Apixaban | Warfarin | Apixaban vs warfarin | ||
| Stroke/SE |
|
|||
| 121 to 140 kg | 0.29 (2) | 1.41 (10) | 0.21 (0.05-0.95) |
|
| >140 kg | 0.85 (2) | 0.38 (1) | 2.35 (0.21-25.95) |
|
| Stroke |
|
|||
| 121 to 140 kg | 0.29 (2) | 1.27 (9) | 0.23 (0.05-1.07) |
|
| >140 kg | 0.85 (2) | 0.38 (1) | 2.35 (0.21-25.95) |
|
| Ischemic or uncertain type of stroke |
|
|||
| 121 to 140 kg | 0.29 (2) | 0.84 (6) | 0.34 (0.07-1.72) |
|
| >140 kg | 0.85 (2) | 0.00 (0) | - |
|
| Hemorrhagic stroke |
|
|||
| 121 to 140 kg | 0.00 (0) | 0.42 (3) | - |
|
| >140 kg | 0.00 (0) | 0.38 (1) | - |
|
| All-Cause death |
|
|||
| 121 to 140 kg | 2.88 (20) | 2.34 (17) | 1.23 (0.64-2.35) |
|
| >140 kg | 3.35 (8) | 2.98 (8) | 1.14 (0.43-3.04) |
|
| Myocardial infarction |
|
|||
| 121 to 140 kg | 0.29 (2) | 0.28 (2) | 1.05 (0.15-7.44) |
|
| >140 kg | 0.43 (1) | 0.76 (2) | 0.54 (0.05-5.92) |
|
Favors apixaban
Favors warfarin
